caa a22 4500 465789889 CHVBK 20180323112020.0 cr unu---uuuuu 170327e19901101xx s 000 0 eng 10.1007/BF00198595 doi (NATIONALLICENCE)springer-10.1007/BF00198595 Phase II trial of echinomycin in advanced soft tissue sarcomas [Elektronische Daten] A Southwest Oncology Group study [Sarah Taylor, Barbara Metch, Stanley Balcerzak, Karl Hanson] Summary: Thirty-four patients with advanced soft tissue sarcomas were entered in a phase II trial of echinomycin. Patients received 1.2 mg/m2 intravenously (i.v.) weekly times four followed by a two week rest period. There were no objective responses. Dose limiting toxicity was gastrointestinal. Echinomycin given on this weekly schedule is inactive in treating previously treated patients with advanced soft tissue sarcomas. Kluwer Academic Publishers, 1990 phase II trial nationallicence soft tissue sarcoma nationallicence echinomycin nationallicence Taylor Sarah University of Kansas Medical Center, Kansas City, KS, USA aut Metch Barbara Southwest Oncology Group Statistical Center, Seattle, WA, USA aut Balcerzak Stanley Ohio State University Health Center, Columbus, OH, USA aut Hanson Karl Midwest Community Clinical Oncology Program, Kansas City, MO, USA aut Investigational New Drugs Kluwer Academic Publishers 8/4(1990-11-01), 381-383 0167-6997 8:4<381 1990 8 10637 https://doi.org/10.1007/BF00198595 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00198595 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Taylor Sarah University of Kansas Medical Center, Kansas City, KS, USA aut NATIONALLICENCE 700 1- Metch Barbara Southwest Oncology Group Statistical Center, Seattle, WA, USA aut NATIONALLICENCE 700 1- Balcerzak Stanley Ohio State University Health Center, Columbus, OH, USA aut NATIONALLICENCE 700 1- Hanson Karl Midwest Community Clinical Oncology Program, Kansas City, MO, USA aut NATIONALLICENCE 773 0- Investigational New Drugs Kluwer Academic Publishers 8/4(1990-11-01), 381-383 0167-6997 8:4<381 1990 8 10637 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer